Parkinson’s disease and Huntington’s disease are caused by the death of nerve cells in the part of the brain called basal ganglia.
Our goal is to develop and improve treatments for the diseases and to improve quality of life for patients and their families.
The World Parkinson Coalition, host of the triennial World Parkinson Congresses, has released their first podcast episode in a series that aims to survey the landscape of Parkinson's disease research and treatment by interviewing neuroscientists, neurologists, and people with Parkinson. The podcast, Portland Countdown, can be found on ITunes and other platforms for podcasts. For more information - CLICK HERE
On April 10th MultiPark, BAGADILICO and Parkinson Skåne invited the public to a full-day event aimed at raising awareness about Parkinson’s and the research dedicated towards the disease. The event was tied to the World Parkinson Day, which took place the following day. MultiPark scientists Malin Parmar and Tomas Björklund discussed approaching clinical trials in the fields of cell therapy and gene therapy. Young scientists participated in a lively Science Slam contest where they gave brief popular science talks hoping to grab the audience’s attention as they battled for first prize.
Inflammation is a natural reaction of the body’s immune system to an aggressor or an injury, but if the inflammatory response is too strong it becomes harmful. Inflammatory processes occur in the brain in conjunction with stroke and neurological diseases such as Alzheimer’s and Parkinson’s disease. Researchers from Lund University and Karolinska Institutet in close collaboration with University of Seville have presented new findings about some of the ‘key players’ in inflammation. In the long term, these findings could lead to new treatments. The findings are published in the scientific journal Cell Reports.
Researchers have long sought treatments that can slow the progression of Parkinson's disease. Current treatments have for decades been only symptomatic in nature, supplying the neurotransmitter dopamine, which the dying nerve cells can no longer produce. Results from a recent clinical study offer hope that future therapies could take advantage of the brain's own protective mechanisms to limit neuronal cell death and restore dopamine production to natural levels.
Involuntary dyskinetic movements induced by treatment with levodopa (L-dopa) are a common problem for people with Parkinson’s disease. Now, however, researchers at Karolinska Institutet and Lund Universityseem to be close to a novel therapy to this distressing side effect. A treatment study published in the journal Brain shows that a drug that stimulates certain serotonin receptors in the brain counteracts the dyskinesia causing effects of L-dopa.